Corrigendum: An orally available small molecule that targets soluble TNF to deliver anti-TNF biologic-like efficacy in rheumatoid arthritis

• Alexander Vugler,
• James O’connell,
• Mai Anh Nguyen,
• Dietmar Weitz,
• Thomas Leeuw,
• Elizabeth Hickford,
• Alexander Verbitsky,
• Xiaoyou Ying,
• Markus Rehberg,
• Bruce Carrington,
• Mark Merriman,
• Andrew Moss,
• Jean-Marie Nicolas,
• Phil Stanley,
• Sara Wright,
• Tim Bourne,
• Yann Foricher,
• Zhaoning Zhu,
• Daniel Brookings,
• Helen Horsley,
• Jag Heer,
• Laurent Schio,
• Matthias Herrmann,
• Srinivas Rao,
• Markus Kohlmann,
• Peter Florian

Affiliations

Alexander Vugler

Immunology Therapeutic Area, PV Early Solutions, UCB Pharma, Slough, United Kingdom

James O’connell

Discovery Sciences, PV Early Solutions, UCB Pharma, Slough, United Kingdom

Mai Anh Nguyen

Sanofi R&D, TMED Pharmacokinetics Dynamics and Metabolism, Frankfurt am Main, Germany

Dietmar Weitz

Sanofi R&D, Drug Metabolism and Pharmacokinetics, Frankfurt am Main, Germany

Thomas Leeuw

Sanofi R&D, Type 1/17 Immunology, Immunology and Inflammation Research TA, Frankfurt, Germany

Elizabeth Hickford

Development Science, PV Early Solutions, UCB Pharma, Slough, United Kingdom

Alexander Verbitsky

Sanofi R&D, Translation In vivo Models, Cambridge, MA, United States

Xiaoyou Ying

Sanofi R&D, Translation In vivo Models, Cambridge, MA, United States

Markus Rehberg

Sanofi R&D, Translational Disease Modelling, Frankfurt am Main, Germany

Bruce Carrington

Discovery Sciences, PV Early Solutions, UCB Pharma, Slough, United Kingdom

Mark Merriman

Immunology Therapeutic Area, PV Early Solutions, UCB Pharma, Slough, United Kingdom

Andrew Moss

Translational Medicine Immunology, PV Early Solutions, UCB Pharma, Slough, United Kingdom

Jean-Marie Nicolas

0Development Science, Drug Metabolism and Pharmacokinetics, UCB Pharma, Braine-I’Alleud, Belgium

Phil Stanley

Immunology Therapeutic Area, PV Early Solutions, UCB Pharma, Slough, United Kingdom

Sara Wright

1Early PV Missions, PV Early Solutions, UCB Pharma, Slough, United Kingdom

Tim Bourne

2Milvuswood Consultancy, Penn, United Kingdom

Yann Foricher

3Sanofi R&D, Integrated Drug Discovery, Vitry-sur-Seine, France

Zhaoning Zhu

4Global Chemistry, Discovery Sciences, PV Early Solutions, UCB Pharma, Slough, United Kingdom

Daniel Brookings

4Global Chemistry, Discovery Sciences, PV Early Solutions, UCB Pharma, Slough, United Kingdom

Helen Horsley

4Global Chemistry, Discovery Sciences, PV Early Solutions, UCB Pharma, Slough, United Kingdom

Jag Heer

4Global Chemistry, Discovery Sciences, PV Early Solutions, UCB Pharma, Slough, United Kingdom

Laurent Schio

3Sanofi R&D, Integrated Drug Discovery, Vitry-sur-Seine, France

Matthias Herrmann

Sanofi R&D, Type 1/17 Immunology, Immunology and Inflammation Research TA, Frankfurt, Germany

Srinivas Rao

Sanofi R&D, Translation In vivo Models, Cambridge, MA, United States

Markus Kohlmann

5Sanofi R&D, Early Clinical Development, Therapeutic Area Immunology and Inflammation, Frankfurt am Main, Germany

Peter Florian

Sanofi R&D, Type 1/17 Immunology, Immunology and Inflammation Research TA, Frankfurt, Germany